Carisma Therapeutics Faces Delisting Concerns

Ticker: CARM · Form: 8-K · Filed: Jul 15, 2025 · CIK: 1485003

Sentiment: bearish

Topics: delisting, listing-standards, regulatory-filing

TL;DR

Carisma's in danger of being delisted, major red flag!

AI Summary

Carisma Therapeutics Inc. filed an 8-K on July 15, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The earliest event reported was on July 9, 2025. The company, formerly known as Sesen Bio, Inc. and Eleven Biotherapeutics, Inc., is incorporated in Delaware and based in Philadelphia, PA.

Why It Matters

This filing indicates potential issues with Carisma Therapeutics' continued listing on an exchange, which could significantly impact its stock value and operational stability.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's future trading and financial health.

Key Players & Entities

FAQ

What specific listing rule or standard has Carisma Therapeutics Inc. failed to satisfy?

The filing does not specify the exact rule or standard that Carisma Therapeutics Inc. has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.

What is the earliest date of the event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on July 9, 2025.

When was this 8-K filing submitted to the SEC?

This 8-K filing was submitted to the SEC on July 15, 2025.

What were Carisma Therapeutics Inc.'s previous names?

Carisma Therapeutics Inc. was formerly known as Sesen Bio, Inc. and Eleven Biotherapeutics, Inc.

Where is Carisma Therapeutics Inc. incorporated and headquartered?

Carisma Therapeutics Inc. is incorporated in Delaware and headquartered at 3675 Market Street, Suite 401, Philadelphia, PA.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on July 15, 2025 regarding Carisma Therapeutics Inc. (CARM).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing